Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and dose-finding study of MOD-4023 in pediatric growth hormone deficiency
2011-004553-60Phase 2Completed
- Sponsor
- OPKO Biologics
- Start
- Nov 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of somatrogon in growth hormone deficiency (GHD) (4 arms), sponsored by OPKO Biologics. Primary endpoint: Annual Height Velocity at 12 months. Started Nov 2011; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2011-004553-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004553-60.